TY - JOUR T1 - Identification of Survival Genes in Human Glioblastoma Cells Using siRNA Screening JF - Molecular Pharmacology JO - Mol Pharmacol DO - 10.1124/mol.109.058024 SP - mol.109.058024 AU - Nikhil G Thaker AU - Fang Zhang AU - Peter R. McDonald AU - Tong Ying Shun AU - Michael D Lewen AU - Ian F. Pollack AU - John S. Lazo Y1 - 2009/01/01 UR - http://molpharm.aspetjournals.org/content/early/2009/09/28/mol.109.058024.abstract N2 - Target identification and validation remain difficult steps in the drug discovery process, and uncovering the core genes and pathways that are fundamental for cancer cell survival may facilitate this process. Therefore, we implemented a short interfering RNA (siRNA) screen with 16,560 siRNAs targeting 5,520 unique druggable human genes aimed at identifying these survival genes in the T98G glioma cell line because glioblastoma represents a challenging form of cancer for chemotherapy. We analyzed cell viability at 96 hr after siRNA transfection with two orthogonal statistical methods and identified 55 survival genes that encoded proteases, kinases, and transferases. Interestingly, 22% (12/55) of the survival genes were constituents of the 20S and 26S proteasome subunits. An expression survey of a panel of glioma cell lines demonstrated expression of the proteasome component PSMB4, and the validity of the proteasome complex as a target for survival inhibition was confirmed in a series of glioma and non-glioma cell lines by pharmacological inhibition and RNA interference. Biological networks were built with the other survival genes using a protein-protein interaction network, which identified clusters of cellular processes, including protein ubiquitination, purine and pyrimidine metabolism, nucleotide excision repair, and NF-κB signaling. The results of this study should broaden our understanding of the core genes and pathways that regulate cell survival, and we highlight the potential significance of proteasome inhibition, through either small molecule inhibition or RNA interference.The American Society for Pharmacology and Experimental Therapeutics ER -